DOCSLIB.ORG

Addition of an Aldosterone Blocker, Spironolactone, to Combination Treatment with an Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Addition of an Aldosterone Blocker, Spironolactone, to Combination Treatment with an Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker 59 Hypertens Res Vol.31 (2008) No.1 p.57-65 Original Article Effect of Renin-Angiotensin-Aldosterone System Triple Blockade on Non-Diabetic Renal Disease: Addition of an Aldosterone Blocker, Spironolactone, to Combination Treatment with an Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Yoshiyuki FURUMATSU1),2), Yasuyuki NAGASAWA2), Kodo TOMIDA1),2), Satoshi MIKAMI1),2), Tetsuya KANEKO1), Noriyuki OKADA1), Yoshiharu TSUBAKIHARA1), Enyu IMAI2), and Tatsuya SHOJI1) Although dual blockade of the renin-angiotensin-aldosterone system (RAAS) with the combination of an angiotensin-converting enzyme inhibitor (ACE-I) and angiotensin II receptor blocker (ARB) is generally well- established as a treatment for nephropathy, this treatment is not fully effective in some patients. Based on the recent evidence implicating aldosterone in renal disease progression, this study was conducted to examine the efficacy of blockade with three different mechanisms by adding an aldosterone blocker in patients who do not respond adequately to the dual blockade. A 1-year randomized, open-label, multicenter, prospective controlled study was conducted, in which 32 non-diabetic nephropathy patients with proteinuria exceeding 0.5 g/day were enrolled after more than 12 weeks of ACE-I (5 mg enalapril) and ARB (50 mg losar- tan) combination treatment. These patients were allocated into two groups of 16 patients each: a triple blockade group in which 25 mg of spironolactone daily was added to the ACE-I and ARB combination treat- ment, and a control group in which 1 mg of trichlormethiazide or 20 mg of furosemide was added to the combination treatment instead of spironolactone depending upon the creatinine level. After 1 year of treat- ment, the urinary protein level decreased by 58% (p<0.05) with the triple blockade but was unchanged in the controls. Furthermore, urinary type IV collagen level decreased by 40% (p<0.05) with the triple blockade but was unchanged in the controls. The decreases in urinary protein and urinary type IV collagen were not accompanied by a decrease in blood pressure. Mean serum creatinine, potassium and blood pressure did not change significantly by either treatment. In conclusion, triple blockade of the RAAS was effective for the treatment of proteinuria in patients with non-diabetic nephropathy whose increased urinary protein had not responded sufficiently to a dual blockade. (Hypertens Res 2008; 31: 59–67) Key Words: spironolactone, aldosterone, angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, proteinuria From the 1)Department of Kidney Disease and Hypertension, Osaka General Medical Center, Osaka, Japan; 2)Department of Nephrology, Osaka Univer- sity Graduate School of Medicine, Suita, Japan. Address for Reprints: Enyu Imai, M.D., Department of Nephrology, Osaka University Graduate School of Medicine, 2–2 Yamadaoka (A8), Suita 565– 0871, Japan. E-mail: [email protected]; Tatsuya Shoji, M.D., Department of Kidney Disease and Hypertension, Osaka General Medical Center, 3–1–56 Bandai-Higashi, Sumiyoshi, Osaka 558–8558, Japan. E-mail: [email protected] Received February 14, 2007; Accepted in revised form August 3, 2007. 60 Hypertens Res Vol. 31, No. 1 (2008) Run-in Period Introduction -12 W 0 W 52 W The renin-angiotensin-aldosterone system (RAAS), and par- Triple Blockade group Dual Blockade ticularly angiotensin II (AII), is recognized to be a major con- +Spironolactone 25 mg tributor to the progression of kidney disease. Solid evidence Enalapril 5 mg + has established the effectiveness of angiotensin-converting Losartan 50 mg Control group enzyme inhibitors (ACE-Is) or angiotensin II receptor block- Cr<1.8 : +Trichlormethiazide 1 mg ers (ARBs) in lessening the contribution of the AII and Cr 1.8 : +Furosemide 10 mg thereby ameliorating kidney disease. Furthermore, dual blockade with an ACE-I and ARB has been reported to be Fig. 1. Study protocol. W, weeks. superior to single blockade both in reducing proteinuria and in slowing the progression of renal disease (1–3). However, some patients do not respond adequately to the conventional sion and exclusion criteria defined below. renin-angiotensin system (RAS) blockade, raising a clinical Inclusion criteria were an age of 20–70 years; controlled problem that remains to be solved. This therapeutic inade- blood pressure (BP) below 130/80 mmHg; chronic nephropa- quacy might be attributable to such putative mechanisms as thy, as defined by serum creatinine concentration below 3.0 non-RAAS stimulators (4, 5), aldosterone breakthrough (6– mg/dL or calculated creatinine clearance of more than 30 mL/ 9), or a vicious cycle within the RAAS in which aldosterone min/1.73 m2; daily treatment with 5 mg enalapril and 50 mg perpetuates both the expression of ACE and that of AII type 1 losartan for 12 weeks or longer; and persistent proteinuria, receptor (10–12). defined as urinary protein excretion exceeding 0.5 g/day. Recently, not only AII but also aldosterone has been recog- Exclusion criteria were diabetes mellitus (HbA1c 5.8% or nized as playing a key role in the RAAS (5, 13). In fact, sev- more); urinary-tract infection; severe renal failure, defined as eral clinical studies have demonstrated that monotherapy with a serum creatinine concentration more than 3.0 mg/dL; an aldosterone blocker (14–16) or combination therapy with uncontrolled hyperkalemia, defined as a serum potassium an aldosterone blocker plus an ACE-I or ARB reduced pro- concentration more than 5.0 mEq/L; treatment-resistant teinuria in patients with chronic kidney disease (CKD) (17– edema; requirement of treatment with corticosteroids, non- 21). However, Chrysostomou, who first reported the antipro- steroidal anti-inflammatory drugs, or immunosuppressive teinuric effect of spironolactone (17), could not prove the effi- drugs; proteinuria greater than 5.0 g/g·Cr; hypoalbuminemia cacy of triple blockade with spironolactone plus an ACE-I less than 2.8 g/dL; renovascular hypertension; malignant and ARB in a later report (22). To date, therefore, the efficacy hypertension; myocardial infarction; cerebrovascular acci- of aldosterone blockade, especially in conjunction with an dent; peripheral vascular disease; heart failure; chronic ACE-I and ARB, has not been confirmed in patients with hepatic disease (rise of serum aminotransferase concentra- CKD. tion); connective-tissue disease; obstructive uropathy; cancer; We hypothesized that triple blockade of the RAAS with an chronic pulmonary disease; drug or alcohol misuse; preg- aldosterone blocker plus an ACE-I and ARB might be more nancy; breast-feeding; and history of allergic reaction to effective than the dual blockade both in reducing proteinuria drugs, especially ACE-Is or ARBs. and in slowing the progression of renal disease, especially in patients whose proteinuria did not respond sufficiently to the Protocol dual blockade. Accordingly, we conducted a 1-year random- ized study to assess the efficacy of an aldosterone blocker; Among the 38 eligible patients, 6 were excluded because they spironolactone, administered in conjunction with an ACE-I did not excrete urinary protein of more than 0.5 g/day after and ARB on proteinuria and renal function in comparison the dual blockade with an ACE-I and ARB. The remaining 32 with the additive use of thiazide or loop diuretics along with subjects were randomly divided into two groups: a triple an ACE-I and ARB. blockade group (n=16) and a control group (n=16). In the triple blockade group, we added 25 mg spironolactone to the Methods ongoing treatment with the ACE-I (5 mg enalapril) and ARB (50 mg losartan). Though it has not been clarified whether 25 mg of spironolactone is sufficient for reducing proteinuria, 25 Patients mg was effective in former trials (17, 20, 21, 23, 24). Thus, in A randomized, open-label, multicenter, prospective, con- this study, we set the dosage of spironolactone to 25 mg. In trolled study was conducted at the Osaka General Medical the control group, we added 1 mg trichlormethiazide or 10 mg Center and Osaka University Hospital from 2002 to 2004. furosemide according to the patient’s serum creatinine level Japanese patients who had been treated with the combination (trichlormethiazide for subjects whose creatinine was less of an ACE-I and ARB were screened according to the inclu- than 1.8 mg/dL or furosemide for those whose creatinine level Furumatsu et al: Triple Blockade with ACE-I, ARB and Spironolactone 61 Table 1. Baseline Characteristics of 30 Patients U-Prot/g Cr (g/g Cr) Triple Control 0.6 blockade p (n=15) (n=15) 0.4 ± ± Age (years) 49.8 2.7 53.9 2.7 0.29 0.2 Gender (male/female) 10/5 9/6 0.70 0 4 8 12 week 1 year Height (cm) 166.1±2.1 162.6±1.8 0.22 0 Body weight (kg) 70.2±2.8 64.9±2.4 0.16 BMI (kg/m2) 26.3±1.4 24.4±0.7 0.25 -0.2 Systolic BP (mmHg) 126.4±2.8 129.6±2.5 0.40 -0.4 *p <0.05 Diastolic BP (mmHg) 79.1±2.2 79.4±2.2 0.92 vs. Control Mean BP (mmHg) 94.9±2.2 96.1±2.1 0.69 -0.6 # Cr (mg/dL) 1.07±0.11 1.22±0.10 0.33 Ccr (mL/min/1.73 m2) 91.8±11.8 68.9±7.8 0.12 -0.8 # K (mEq/L) 4.28±0.12 4.28±0.08 0.97 -1.0 ± ± # Albumin (mg/dL) 3.73 0.08 3.64 0.09 0.48 p<0.05 vs. 0 week (Dunnett) T-Cho (mg/dL) 197.0±16.3 172.7±14.7 0.28 -1.2 Ht (%) 40.3±1.2 39.1±1.3 0.48 Fig. 2. Changes in proteinuria.
Load more

Recommended publications
  • High-Throughput Screening Studies of Inhibition of Human Carbonic Anhydrase II and Bacterial Flagella Antimicrobial Activity
    Western Michigan University ScholarWorks at WMU Dissertations Graduate College 5-2010 High-Throughput Screening Studies of Inhibition of Human Carbonic Anhydrase II and Bacterial Flagella Antimicrobial Activity Albert A. Barrese III Western Michigan University Follow this and additional works at: https://scholarworks.wmich.edu/dissertations Part of the Biochemistry, Biophysics, and Structural Biology Commons, and the Biology Commons Recommended Citation Barrese, Albert A. III, "High-Throughput Screening Studies of Inhibition of Human Carbonic Anhydrase II and Bacterial Flagella Antimicrobial Activity" (2010). Dissertations. 500. https://scholarworks.wmich.edu/dissertations/500 This Dissertation-Open Access is brought to you for free and open access by the Graduate College at ScholarWorks at WMU. It has been accepted for inclusion in Dissertations by an authorized administrator of ScholarWorks at WMU. For more information, please contact [email protected]. HIGH-THROUGHPUT SCREENING STUDIES OF INHIBITION OF HUMAN CARBONIC ANHYDRASE II AND BACTERIAL FLAGELLA ANTIMICROBIAL ACTIVITY by Albert A. Barrese III A Dissertation Submitted to the Faculty of The Graduate College in partial fulfillment of the requirements for the Degree of Doctor of Philosophy Department of Biological Sciences Advisor: Brian C. Tripp, Ph.D. Western Michigan University Kalamazoo, Michigan May 2010 UMI Number: 3410393 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. UMT Dissertation Publishing UMI 3410393 Copyright 2010 by ProQuest LLC.
    [Show full text]
  • DIURETICS Diuretics Are Drugs That Promote the Output of Urine Excreted by the Kidneys
    DIURETICS Diuretics are drugs that promote the output of urine excreted by the Kidneys. The primary action of most diuretics is the direct inhibition of Na+ transport at one or more of the four major anatomical sites along the nephron, where Na+ reabsorption takes place. The increased excretion of water and electrolytes by the kidneys is dependent on three different processes viz., glomerular filtration, tubular reabsorption (active and passive) and tubular secretion. Diuretics are very effective in the treatment of Cardiac oedema, specifically the one related with congestive heart failure. They are employed extensively in various types of disorders, for example, nephritic syndrome, diabetes insipidus, nutritional oedema, cirrhosis of the liver, hypertension, oedema of pregnancy and also to lower intraocular and cerebrospinal fluid pressure. Therapeutic Uses of Diuretics i) Congestive Heart Failure: The choice of the diuretic would depend on the severity of the disorder. In an emergency like acute pulmonary oedema, intravenous Furosemide or Sodium ethacrynate may be given. In less severe cases. Hydrochlorothiazide or Chlorthalidone may be used. Potassium-sparing diuretics like Spironolactone or Triamterene may be added to thiazide therapy. ii) Essential hypertension: The thiazides usually sever as primary antihypertensive agents. They may be used as sole agents in patients with mild hypertension or combined with other antihypertensives in more severe cases. iii) Hepatic cirrhosis: Potassium-sparing diuretics like Spironolactone may be employed. If Spironolactone alone fails, then a thiazide diuretic can be added cautiously. Furosemide or Ethacrymnic acid may have to be used if the oedema is regractory, together with spironolactone to lessen potassium loss. Serum potassium levels should be monitored periodically.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • The Uricosuric Effect in Rats of E5050, a New Derivative of Ethanolamine, Involves Inhibition of the Tubular Postsecretory Reabsorption of Urate
    The Uricosuric Effect in Rats of E5050, a New Derivative of Ethanolamine, Involves Inhibition of the Tubular Postsecretory Reabsorption of Urate Haruko Sugino and Hideyo Shimada Department of Clinical Pharmacology, School of Pharmaceutical Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108, Japan Received January 27, 1995 Accepted April 20, 1995 ABSTRACT-N-{3-[4 (2",6"-Dimethylheptyl)phenyl]butanoyl}ethanolamine (E5050), a newly synthesized compound, was shown recently to induce uricosuria in humans via inhibition of the postsecretory reabsorp- tion of urate. We examined the effects of this compound on urate excretion in rats loaded with oxonate and compared these effects with those of the uricosuric drugs trichlormethiazide and probenecid. When ad- ministered i.p., E5050 (0.3 - 15 mg/kg) increased the urinary excretion rate of urate and the ratio of urate clearance to inulin clearance in a dose-dependent manner, while the urine volume increased only slightly, and the glomerular filtration rate and plasma urate level were not changed. No paradoxical effect on urate excretion was observed. In contrast, trichlormethiazide and probenecid had a biphasic effect on urate excretion. In a pyrazinoic acid suppression test, the uricosuric effect of E5050 was completely inhibited by pretreatment with pyrazinoic acid. In a phenolsulfonphthalein (PSP) test, E5050 did not affect urinary PSP excretion, while probenecid strongly decreased such excretion. Thus, E5050 also appears to be uricosuric in rats. Keywords: E5050, Uricosuric drug, Pyrazinoic acid, Phenolsulfonphthalein, Urate excretion The renal handling of urate can be explained by the the tubular transport of urate. four-component theory (1); That is, plasma urate is In contrast to the above-described drugs, only a few filtered from the blood at the glomerulus and subsequent- drugs seem to exert a uricosuric action by the selective in- ly undergoes presecretory reabsorption, secretion and hibition of the presecretory or postsecretory reabsorption postsecretory reabsorption at the renal tubule.
    [Show full text]
  • Using Medications, Cosmetics, Or Eating Certain Foods Can Increase Sensitivity to Ultraviolet Radiation
    USING MEDICATIONS, COSMETICS, OR EATING CERTAIN FOODS CAN INCREASE SENSITIVITY TO ULTRAVIOLET RADIATION. INDIVIDUALS SHOULD CONSULT A PHYSICIAN BEFORE USING A SUNLAMP, IF THEY ARE TAKING MEDICATIONS. THE ITEMS LISTED ARE POTENTIAL PHOTOSENSITIZING AGENTS THAT MAY INCREASE SENSITIVITY TO ULTRAVIOLET LIGHT THAT MAY RESULT IN A PHOTOTOXIC OR PHOTOALLERGIC RESPONSES. PHOTOSENSITIZING MEDICATIONS Acetazolamide Amiloride+Hydrochlorothizide Amiodarone Amitriptyline Amoxapine Astemizole Atenolol+Chlorthalidone Auranofin Azatadine (Optimine) Azatidine+Pseudoephedrine Bendroflumethiazide Benzthiazide Bromodiphenhydramine Bromopheniramine Captopril Captopril+Hydrochlorothiazide Carbaamazepine Chlordiazepoxide+Amitriptyline Chlorothiazide Chlorpheniramine Chlorpheniramin+DPseudoephedrine Chlorpromazine Chlorpheniramine+Phenylopropanolamine Chlorpropamide Chlorprothixene Chlorthalidone Chlorthalidone+Reserpine Ciprofloxacin Clemastine Clofazime ClonidineChlorthalisone+Coal Tar Coal Tar Contraceptive (oral) Cyclobenzaprine Cyproheptadine Dacarcazine Danazol Demeclocycline Desipramine Dexchlorpheniramine Diclofenac Diflunisal Ditiazem Diphenhydramine Diphenylpyraline Doxepin Doxycycline Doxycycline Hyclate Enalapril Enalapril+Hydrochlorothiazide Erythromycin Ethylsuccinate+Sulfisoxazole Estrogens Estrogens Ethionamide Etretinate Floxuridine Flucytosine Fluorouracil Fluphenazine Flubiprofen Flutamide Gentamicin Glipizide Glyburide Gold Salts (compounds) Gold Sodium Thiomalate Griseofulvin Griseofulvin Ultramicrosize Griseofulvin+Hydrochlorothiazide Haloperidol
    [Show full text]
  • A New Diuretic That Does Not Reduce Renal Handling of Uric Acid in Rats, S-8666 Yukio YONETANI, Kazumi IWAKI, Mitsuo ISHII and H
    A New Diuretic That Does Not Reduce Renal Handling of Uric Acid in Rats, S-8666 Yukio YONETANI, Kazumi IWAKI, Mitsuo ISHII and Hiroshi HARADA ShionogiResearch Laboratories, Shionogi & Co., Ltd., Fukushima-ku,Osaka 553, Japan AcceptedJanuary 6, 1987 Abstract-The uric acid-retaining effects of diuretics were studied using sodium restricted spontaneously hypertensive rats. Test agents were administered orally once a day for two weeks. Diuretic thiazides such as trichlormethiazide and hydrochlorothiazide and loop diuretics such as furosemide and indacrinone clearly reduced the renal function for uric acid excretion in treatment which produced major effects such as diuresis, saluresis and hypotension. However, a new diuretic with uricosuric activity, S-8666, developed in our laboratories, had no effect on the renal handling of uric acid at doses which showed major effects similar to those of other diuretics. The results should aid the understanding of the utility of S-8666 as a new diuretic antihypertensive which does not cause hyperuricemia during therapy. The high incidence of hyperuricemia to 8666), which is active in rats and chimpanzees hypertension (1, 2) has required the develop (8). We tried to find whether S-8666 affects ment of a new generation of diuretic anti uric acid excretion at a dose which produces hypertensives, which do not cause hyper a major effect, in comparison with other uricemia. Uricosuric diuretics such as tienilic diuretics. Our findings support the utility of acid (3) and indacrinone (4) have recently S-8666 as a new diuretic antihypertensive been studied as such candidates. However, which does not cause hyperuricemia. the results have shown the need for careful testing (5, 6).
    [Show full text]
  • Comparison of Absorbents and Drugs for Internal Decorporation
    Biological and Pharmaceutical Bulletin Advance Publication by J-STAGE Advance Publication DOI:10.1248/bpb.b15-00728 December 25, 2015 Biol. Pharm. Bull. Regular Article Comparison of Absorbents and Drugs for Internal Decorporation of Radiocesium: Advances of Polyvinyl Alcohol Hydrogel Microsphere Preparations Containing Magnetite and Prussian Blue. Izumi Tanaka, Hiroshi Ishihara*, Haruko Yakumaru, Mika Tanaka, Kazuko Yokochi, Katsushi Tajima, Makoto Akashi Internal Decorporation Research Team, Research Program for Radiation Medicine, Research Center for Radiation Emergency Medicine, National Institute of Radiological Sciences, 4-9-1, Anagawa, Inage-ku, Chiba-shi, Chiba 263-85555, Japan *Corresponding author. Internal Decorporation Research Team, Research Program for Radiation Medicine, Research Center for Radiation Emergency Medicine, National Institute of Radiological Sciences, 4-9-1, Anagawa, Inage-ku, Chiba-shi, Chiba 263-85555, Japan. Tel: +81-43-206-3162; Fax: +81-43-284-1769; Email: [email protected] Ⓒ 2015 The Pharmaceutical Society of Japan Summary Radiocesium nuclides, used as a gamma ray source in various types of industrial equipments and found in nuclear waste, are strictly controlled to avoid their leakage into the environment. When large amounts of radiocesium are accidentally incorporated into the human body, decorporation therapy should be considered. Although standard decorporation methods have been studied since the 1960s and were established in the 1970s with the drug Radiogardase® (a Prussian blue preparation), application of recent advances in pharmacokinetics and ethical standards could improve these methods. Here we designed a modern dosage form of hydrogel containing cesium-absorbents to alleviate intestinal mucosa irritation due to the cesium-binding capacity of the absorbents. The effectiveness of the dosage form on fecal excretion was confirmed by quantitative mouse experiments.
    [Show full text]
  • SUPPLEMENTARY FILE Dose Doubling, Relative Potency, and Dose Equivalence of Potassium Sparing Diuretics Affecting Blood Pressure
    SUPPLEMENTARY FILE Dose Doubling, Relative Potency, and Dose Equivalence of Potassium Sparing Diuretics Affecting Blood Pressure and Serum Potassium: Systematic Review and Meta-Analyses George C. Roush,1,2 Michael E. Ernst3, John B. Kostis4, Shamima Yeasmin,2 and Domenic A. Sica5 1Corresponding author 2UCONN School of Medicine and St. Vincent’s Medical Center, Department of Medicine, Bridgeport, CT, USA 3University of Iowa Hospital and Clinics, Department of Family Medicine, Iowa City, IA, USA 4Cardiovascular Institute, UMDNJ-Robert Wood Johnson Medical School, Chairman, Department of Medicine, New Brunswick, NJ, USA 5Department of Medicine and Pharmacology, Virginia Commonwealth University, Richmond, VA, USA METHOD FOR OBTAINING DOSE EQUIVALENCIES To obtain dose equivalency, a generalized method assumes that (1) changes in SBP caused by the log doses of the two drugs, A & B, are linear and fail to “bottom out” at higher doses and (2) dose-response effects for the two drugs are parallel. These assumptions were supported by the data. The general model is: SBP change = I – D*ln(Dose) – E*(1 if drug=A) – E*(0 if drug is B), where I, D, and E are constants. For drug B to compensate for its lesser potency: I – D*ln(Dose of A) – E*1 must equal I –D*ln(Dose of B) – E*0. This comes out to Dose of A = Dose of B*Exp(E/D). REFERENCES FOR META-ANALYSES TRIAMTERENE Kohvakka A, Salo H, Gordin A, Eisalo A. Antihypertensive and biochemical effects of different doses of hydrochlorothiazide alone or in combination with triamterene. Acta Med Scand. 1986;219(4):381-6.
    [Show full text]
  • 38 Scientific Publications in Support of My Testimony I. Effect Of
    Scientific Publications In Support of My Testimony I. Effect Of Furosemide On Performance Of Thoroughbreds Racing In The United States And Canada. Gross DK, Morley PS, Hinchcliff KW, Wittum TE. II. Furosemide Reduces Accumulated Oxygen Deficit In Horses During Brief Intense Exertion. K. W. Hinchcliff, K. H. McKeever, W. W. Muir, and R. A. Sams III. Furosemide-Induced Changes In Plasma And Blood Volume Of Horses. K. W. Hinchcliff, K. H. McKeever, W. W. Muir III IV. Effects Of Dehydration On Thermoregulatory Responses Of Horses During Low- Intensity Exercise. J. R. Naylor, W. M. Bayly, P. D. Gollnick, G. L. Brengelmann, and D. R. Hodgson V. Review Of Furosemide In Horse Racing: Its Effects And Regulation. L.R. Soma1, C.E. Uboh2 VI. Hemoconcentration and Oxygen Carrying Capacity Alteration in Race Horses Following Administration of Furosemide Prior to Speed Work, A Pilot Study. Sheila Lyons DVM, FACVSMR VII. The Use of Blood Doping as an Ergogenic Aid. Sawka, Michael N. Ph.D., FACSM, (Chair); Joyner, Michael J. M.D.; Miles, D. S. Ph.D., FACSM; Robertson, Robert J. Ph.D., FACSM; Spriet, Lawrence L. Ph.D., FACSM; Young, Andrew J. Ph.D., FACSM VIII. Fracture Risk In Patients Treated With Loop Diuretics. L. Rejnmark, P. Vestergaard, L. Mosekilde IX. Soft Palate Problems And Bleeding In Racehorses? The Answer Is On The Tip Of The Horse’s Tongue. Robert Cook FRCVS, PhD X. An Endoscopic Test For Bit-Induced Nasopharyngeal Asphyxia As A Cause Of Exercise-Induced Pulmonary Haemorrhage In The Horse. Robert Cook FRCVS, PhD XI. New York State Racing and Wagering Board Task Force On Racehorse Health and Safety, Official Report, Investigation Of Equine Fatalities At Aqueduct 2011-2012 Fall/Winter Meet.
    [Show full text]
  • The Effect of Trichlormethiazide in Autosomal Dominant Polycystic
    www.nature.com/scientificreports OPEN The efect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial Kiyotaka Uchiyama1,2*, Chigusa Kitayama3, Akane Yanai4 & Yoshitaka Ishibashi2 The vasopressin V2 receptor antagonist tolvaptan delays the progression of autosomal dominant polycystic kidney disease (ADPKD). However, some patients discontinue tolvaptan because of severe adverse aquaretic events. This open-label, randomized, controlled, counterbalanced, crossover trial investigated the efects of trichlormethiazide, a thiazide diuretic, in patients with ADPKD receiving tolvaptan (n = 10) who randomly received antihypertensive therapy with or without trichlormethiazide for 12 weeks. The primary and secondary outcomes included amount and osmolarity of 24-h urine and health-related quality-of-life (HRQOL) parameters assessed by the Kidney Disease Quality of Life-Short Form questionnaire, renal function slope, and plasma/urinary biomarkers associated with disease progression. There was a signifcant reduction in urine volume (3348 ± 584 vs. 4255 ± 739 mL; P < 0.001) and a signifcant increase in urinary osmolarity (182.5 ± 38.1 vs. 141.5 ± 38.1 mOsm; P = 0.001) in patients treated with trichlormethiazide. Moreover, trichlormethiazide improved the following HRQOL subscales: efects of kidney disease, sleep, emotional role functioning, social functioning, and role/social component summary. No signifcant diferences were noted in renal function slope or plasma/urinary biomarkers between patients treated with and without trichlormethiazide. In patients with ADPKD treated with tolvaptan, trichlormethiazide may improve tolvaptan tolerability and HRQOL parameters. Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic renal disorder and one of the leading causes of end-stage kidney disease1.
    [Show full text]
  • Effect of Low-Dose Spironolactone on Resistant Hypertension in Type 2
    Djoumessi et al. BMC Res Notes (2016) 9:187 DOI 10.1186/s13104-016-1987-5 BMC Research Notes RESEARCH ARTICLE Open Access Effect of low‑dose spironolactone on resistant hypertension in type 2 diabetes mellitus: a randomized controlled trial in a sub‑Saharan African population Romance Nguetse Djoumessi1†, Jean Jacques N. Noubiap2,3†, Francois Folefack Kaze1, Mickael Essouma4, Alain Patrick Menanga1, Andre Pascal Kengne5, Jean Claude Mbanya1,6,7 and Eugene Sobngwi1,6,7* Abstract Background: Low-dose spironolactone has been proven to be effective for resistant hypertension in the general population, but this has yet to be confirmed in type 2 diabetic (T2DM) patients. We assessed the efficacy of a low- dose spironolactone on resistant hypertension in a sub-Saharan African population of T2DM patients from Cameroon. Methods: This was a four-week single blinded randomized controlled trial in 17 subjects presenting with resist- ant hypertension in specialized diabetes care units in Cameroon. They were randomly assigned to treatment with a daily 25 mg of spironolactone (n 9) or to an alternative antihypertensive regimen (n 8), on top of any ongoing regimen and prevailing lifestyle prescriptions.= They were seen at the start of the treatment,= then 2 and 4 weeks later. The primary outcome was change in office and self-measured blood pressure (BP) during follow-up, and secondary outcomes were changes in serum potassium, sodium, and creatinine levels. Results: Compared with alternative treatment, low-dose spironolactone was associated with significant decrease in office systolic BP ( 33 vs. 14 mmHg; p 0.024), and in diastolic BP ( 14 vs.
    [Show full text]